Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial

Autor: Bath, P. M. W., Adami, A., Bereczki, D., Berge, E., Beridze, M., Cala, L., Casado, A., Caso, V., Chang, H. M., Christensen, H., Collins, R., Czlonkowska, A., Dineen, R. A., Etribi, A. E., Ghani, A., Gommans, J., Koumellis, P., Laska, A. C., Lees, K. R., Navarro, J., Ntaios, G., Ozturk, S., Phillips, S., Pocock, S., Prasad, K., Scutt, P., de Silva, H. A., Szatmari, S., Exuperio, Diez-Tejedor, Utton, S., Wang, Y. -J., Wardlaw, Joanna M., Whynes, D., Wong, L., Woodhouse, L., Sprigg, N., Enos, Investigators, Sacco, S.
Přispěvatelé: Selçuk Üniversitesi
Rok vydání: 2014
Předmět:
Male
Vasodilator Agents
RATIONALE
BLOOD-PRESSURE
Blood Pressure
STATISTICAL-ANALYSIS
Severity of Illness Index
law.invention
Brain Ischemia
chemistry.chemical_compound
Nitroglycerin
glyceryl trinitrate
DESIGN
Randomized controlled trial
Enos
law
80 and over
Medicine
Single-Blind Method
ACUTE ISCHEMIC-STROKE
Prospective Studies
Prospective cohort study
Stroke
SCALE
Aged
80 and over
OUTCOMES
biology
blood pressure
Middle Aged
Treatment Outcome
Neurology
Anesthesia
antihypertensive drugs
Administration
Female
Adult
medicine.medical_specialty
acute stroke
Administration
Cutaneous
CLINICAL-TRIAL
Nitric oxide
Young Adult
nitric oxide
Internal medicine
Severity of illness
Humans
TRANSDERMAL GLYCERYL TRINITRATE
Antihypertensive Agents
Aged
Cerebral Hemorrhage
business.industry
biology.organism_classification
medicine.disease
Clinical trial
Blood pressure
Cutaneous
chemistry
randomized controlled trial
business
Acute stroke
Antihypertensive drugs
Glyceryl trinitrate
Zdroj: Bath, P M W, Adami, A, Bereczki, D, Berge, E, Beridze, M, Cala, L, Casado, A, Caso, V, Chang, H M, Christensen, H, Collins, R, Czlonkowska, A, Dineen, R A, El Etribi, A, Ghani, A R, Gommans, J, Koumellis, P, Laska, A C, Lees, K R, Navarro, J, Ntaios, G, Ozturk, S, Phillips, S, Pocock, S, Prasad, K, Scutt, P, de Silva, H A, Szatmari, S, Diez-Tejedor, E, Utton, S, Wang, Y-J, Wardlaw, J M, Whynes, D, Wong, L & Woodhouse, L & Sprigg, N 2014, ' Baseline characteristics of the 4011 patients recruited into the 'Efficacy of Nitric Oxide in Stroke' (ENOS) trial ', International Journal of Stroke, vol. 9, no. 6, pp. 711-720 . https://doi.org/10.1111/ijs.12308
ISSN: 1747-4949
DOI: 10.1111/ijs.12308
Popis: WOS: 000339477400012
PubMed: 25043647
Background High blood pressure is common in acute stroke and associated with a worse functional outcome. Many patients who present with acute stroke are taking prescribed antihypertensive therapy before their stroke. Aims ENOS tested whether lowering blood pressure and continuing pre-stroke antihypertensive therapy are each safe and effective. Methods This study is an international multi-centre prospective randomized single-blind blinded-endpoint parallel-group partial-factorial controlled trial of transdermal glyceryl trinitrate (a nitric oxide donor, given for seven-days) vs. no glyceryl trinitrate, and of continuing vs. stopping (temporarily for seven-days) pre-stroke antihypertensive drugs if relevant, in patients with acute ischaemic stroke or intracerebral haemorrhage and high systolic blood pressure (140-220 mmHg). Results Recruitment ran from July 2001 to October 2013. Four thousand eleven patients [2097 (52.3%) in the continue/stop arm] were recruited from 173 sites across 23 countries in 5 continents (Asia 14%, Continental Europe 16%, UK 64%). Baseline characteristics include: mean age 70 (standard deviation 12) years; male 57%; mean time from stroke to recruitment 26 (13) h; mean severity (Scandinavian Stroke Scale) 34 (13) of 58; mean blood pressure 167 (19)/90 (13) mmHg; ischaemic stroke 83%; and intracerebral haemorrhage 16%. The main trial results will be presented in May 2014. The results will also be presented in updated Cochrane systematic reviews and included in individual patient data meta-analyses of all relevant randomized controlled trials. Conclusion ENOS is a large completed international trial of blood pressure management in acute stroke and includes patients representative of many stroke services worldwide.
UK Medical Research CouncilMedical Research Council UK (MRC); Bupa Foundation; Hypertension Trust; Queen Elizabeth II Health Sciences Centre Research Fund; Reichstadt family; Stroke Association; UK NIHR, through the Stroke Research Network
We thank all the patients, and their carers, for participating in the trial. The UK Medical Research Council was the primary funder; we thank them and other funders who supported the trial: A Star, Bupa Foundation, Hypertension Trust, Queen Elizabeth II Health Sciences Centre Research Fund, Reichstadt family, and The Stroke Association (through its funding of the Division of Stroke, University of Nottingham). ENOS acknowledges the support of the UK NIHR, through the Stroke Research Network. Finally, we thank the members of the independent data monitoring committee who supervised safety from the beginning to the end of the trial.
Databáze: OpenAIRE
Externí odkaz: